Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.]

Recenti progressi in medicina - 1 May 2024

Cerro Marianna, Maccallini Maria Teresa, Russillo Michelangelo

Abstract excerpt

Paraneoplastic leukemoid reaction (PLR) is an extremely rare condition in patients with melanoma and it is frequently associated with poor prognosis. BRAF gene mutational analysis represents the gold standard in patients with inoperable or metastatic melanoma as the possible presence of target mutations allows the use of the combination treatment with BRAF and MEK inhibitors. In this article, the case of a young...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Sulfonamides

Share to Treatment Outcome

Source

Identifiers

PMID: 38708541
DOI: 10.1701/4262.42409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.]PMID 38708541Read ↗

Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma.Semantic proximity Read ↗

[Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].Semantic proximity Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].Semantic proximity Read ↗

Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).Semantic proximity Read ↗

Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass.Semantic proximity Read ↗

Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report.Semantic proximity Read ↗

Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.Semantic proximity Read ↗

[MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma].Semantic proximity Read ↗

Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report.Semantic proximity Read ↗

[Treatment combinations in BRAF-mutant metastatic melanoma.]Semantic proximity Read ↗

Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.